Clinical and Epidemiological Changes in French Soldiers After Deployment: Impact of Doxycycline Malaria Prophylaxis on Body Weight.


Journal

Military medicine
ISSN: 1930-613X
Titre abrégé: Mil Med
Pays: England
ID NLM: 2984771R

Informations de publication

Date de publication:
16 05 2023
Historique:
received: 12 07 2021
revised: 21 09 2021
accepted: 12 10 2021
medline: 18 5 2023
pubmed: 27 10 2021
entrez: 26 10 2021
Statut: ppublish

Résumé

Antibiotics are growth promotors used in animal farming. Doxycycline (DOXY) is a tetracycline antibiotic taken daily and continued 1 month after return to protect against malaria during travel and deployment in endemic areas. We evaluated DOXY impact on body weight in military international travelers. A prospective cohort analysis was conducted in 2016-2018, recruiting 170 French soldiers before a 4-month assignment overseas. Many clinical data including anthropometric measures by an investigator were collected before and after deployment. Weight gain was defined by an increase of 2% from baseline. The study protocol was supported by the French Armed Forces Health Services and approved by the French ethics committee (IRB no. 2015-A01961-48, ref promoter 2015RC0). Written, informed consent was obtained with signature from each volunteer before inclusion. After deployment, 84 soldiers were followed up. Overall, 38/84 (45%) were deployed to Mali with DOXY malaria prophylaxis, and others were deployed to Iraq or Lebanon without malaria prophylaxis according to international recommendations. Body weight increased in 24/84 (30%), of whom 14/24 (58%) were exposed to DOXY. In bivariate analysis, DOXY had a positive but not significant effect on weight gain (P-value = .4). In the final logistic regression model (Fig. 3), weight gain after deployment positively correlated with an increase in waist circumference (odds ratio [OR] 1.23 with 95% CI [1.06-1.47]) suggesting fat gain; with sedentary work (OR 5.34; 95% CI [1.07-31.90]); and with probiotic intake (OR 5.27; 95% CI [1.51-20.40]). Weight impact of probiotics was more important when associated with DOXY intake (OR 6.86; 95% CI [1.52-38.1]; P-value = .016). Doxycycline (DOXY) malaria prophylaxis during several months did not cause significant weight gain in soldiers. Further studies are required in older and less sportive traveling populations, and to investigate a cumulative effect over time and recurrent DOXY exposure. Doxycycline (DOXY) may enhance other growth-promoting factors including fatty food, sedentariness, and strain-specific probiotics contained in fermented dairy products which are also used as growth promotors.

Sections du résumé

BACKGROUND
Antibiotics are growth promotors used in animal farming. Doxycycline (DOXY) is a tetracycline antibiotic taken daily and continued 1 month after return to protect against malaria during travel and deployment in endemic areas. We evaluated DOXY impact on body weight in military international travelers.
MATERIEL AND METHODS
A prospective cohort analysis was conducted in 2016-2018, recruiting 170 French soldiers before a 4-month assignment overseas. Many clinical data including anthropometric measures by an investigator were collected before and after deployment. Weight gain was defined by an increase of 2% from baseline. The study protocol was supported by the French Armed Forces Health Services and approved by the French ethics committee (IRB no. 2015-A01961-48, ref promoter 2015RC0). Written, informed consent was obtained with signature from each volunteer before inclusion.
RESULTS
After deployment, 84 soldiers were followed up. Overall, 38/84 (45%) were deployed to Mali with DOXY malaria prophylaxis, and others were deployed to Iraq or Lebanon without malaria prophylaxis according to international recommendations. Body weight increased in 24/84 (30%), of whom 14/24 (58%) were exposed to DOXY. In bivariate analysis, DOXY had a positive but not significant effect on weight gain (P-value = .4). In the final logistic regression model (Fig. 3), weight gain after deployment positively correlated with an increase in waist circumference (odds ratio [OR] 1.23 with 95% CI [1.06-1.47]) suggesting fat gain; with sedentary work (OR 5.34; 95% CI [1.07-31.90]); and with probiotic intake (OR 5.27; 95% CI [1.51-20.40]). Weight impact of probiotics was more important when associated with DOXY intake (OR 6.86; 95% CI [1.52-38.1]; P-value = .016).
CONCLUSIONS
Doxycycline (DOXY) malaria prophylaxis during several months did not cause significant weight gain in soldiers. Further studies are required in older and less sportive traveling populations, and to investigate a cumulative effect over time and recurrent DOXY exposure. Doxycycline (DOXY) may enhance other growth-promoting factors including fatty food, sedentariness, and strain-specific probiotics contained in fermented dairy products which are also used as growth promotors.

Identifiants

pubmed: 34697624
pii: 6410150
doi: 10.1093/milmed/usab434
doi:

Substances chimiques

Doxycycline N12000U13O
Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1084-e1093

Informations de copyright

© The Association of Military Surgeons of the United States 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Emilie Javelle (E)

Infectious Diseases and Tropical Diseases unit, Laveran Military Teaching Hospital, Marseille 13013, France.
IRD, AP-HM, SSA, VITROME, Aix-Marseille University, Marseille 13385, France.
IHU-Méditerranée Infection, Marseille 13005, France.

Aurélie Mayet (A)

Centre d'Epidémiologie et de Santé Publique des Armées (CESPA), Marseille 13014, France.
INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, SITE SANTÉ TIMONE (QuanTIM-SanteRCom) Faculté de Médecine, Aix-Marseille University, Marseille Cedex 5 13385, France.

Rodrigue S Allodji (RS)

Radiation Epidemiology Team, CESP, Inserm U1018, Villejuif 94 807, France.
UVSQ, Inserm, CESP, Université Paris-Saclay, Villejuif 94 807, France.
Department of Research, Gustave Roussy, 94805, Villejuif, France.

Catherine Marimoutou (C)

Centre d'Epidémiologie et de Santé Publique des Armées (CESPA), Marseille 13014, France.
INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, SITE SANTÉ TIMONE (QuanTIM-SanteRCom) Faculté de Médecine, Aix-Marseille University, Marseille Cedex 5 13385, France.
CIC Inserm 1410, CHU de La Réunion, Site Sud, Saint Pierre Cedex 97448, France.

Chrystel Lavagna (C)

Centre d'Epidémiologie et de Santé Publique des Armées (CESPA), Marseille 13014, France.

Jérôme Desplans (J)

Centre d'Epidémiologie et de Santé Publique des Armées (CESPA), Marseille 13014, France.

Matthieu Million (M)

IHU-Méditerranée Infection, Marseille 13005, France.
IRD, AP-HM, SSA, MEPHI, Aix-Marseille University, Marseille 13385, France.

Didier Raoult (D)

IHU-Méditerranée Infection, Marseille 13005, France.
IRD, AP-HM, SSA, MEPHI, Aix-Marseille University, Marseille 13385, France.

Gaëtan Texier (G)

IRD, AP-HM, SSA, VITROME, Aix-Marseille University, Marseille 13385, France.
Centre d'Epidémiologie et de Santé Publique des Armées (CESPA), Marseille 13014, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH